| (Values in U.S. Thousands) | Oct, 2025 | Jul, 2025 | Apr, 2025 | Jan, 2025 | Oct, 2024 |
| Sales | 350 | 620 | 670 | 640 | 650 |
| Sales Growth | -43.55% | -7.46% | +4.69% | -1.54% | +47.73% |
| Net Income | -3,870 | -2,000 | -1,390 | -5,520 | -1,360 |
| Net Income Growth | -93.50% | -43.89% | +74.82% | -305.88% | +20.47% |
Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company is engaged in developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. Nutriband Inc. is based in Orlando, United States.
Fiscal Year End Date: 01/31